PANACEA BIOTECH has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Net Sales | Rs m | 5,301 | 5,894 | 11.2% |
Other income | Rs m | 466 | 82 | -82.3% |
Total Revenues | Rs m | 5,767 | 5,977 | 3.6% |
Gross profit | Rs m | 548 | 845 | 54.2% |
Depreciation | Rs m | 680 | 585 | -13.9% |
Interest | Rs m | 1,009 | 1,006 | -0.3% |
Profit before tax | Rs m | -675 | -663 | -1.6% |
Tax | Rs m | -110 | 99 | -189.8% |
Profit after tax | Rs m | -565 | -762 | 34.9% |
Gross profit margin | % | 10.3 | 14.3 | |
Effective tax rate | % | 16.3 | -14.9 | |
Net profit margin | % | -10.7 | -12.9 |
Act Before 11:59pm: Last Day to SAVE 80% on Our Midcap Stocks Research
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | % Change | |
---|---|---|---|---|
Networth | Rs m | 3,557 | 3,087 | -13.2 |
Current Liabilities | Rs m | 6,891 | 6,955 | 0.9 |
Long-term Debt | Rs m | 7,141 | 5,707 | -20.1 |
Total Liabilities | Rs m | 17,741 | 15,924 | -10.2 |
Current assets | Rs m | 7,032 | 5,648 | -19.7 |
Fixed Assets | Rs m | 10,709 | 10,275 | -4.0 |
Total Assets | Rs m | 17,741 | 15,924 | -10.2 |
Particulars | No. of months | 12 | 12 | % Change |
---|---|---|---|---|
Year Ending | Mar-17 | Mar-18 | ||
Cash Flow from Operating Activities | Rs m | 1,307 | 1,180 | -9.7% |
Cash Flow from Investing Activities | Rs m | -258 | 553 | - |
Cash Flow from Financing Activities | Rs m | -1,070 | -1,643 | - |
Net Cash Flow | Rs m | -21 | 90 | - |
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Sales per share (Unadj.) | Rs | 86.5 | 96.2 |
TTM Earnings per share | Rs | -9.2 | -12.4 |
Diluted earnings per share | Rs | -9.2 | -12.4 |
Price to Cash Flow | x | 85.7 | -85.5 |
TTM P/E ratio | x | -11.4 | -22.8 |
Price / Book Value ratio | x | 2.3 | 4.9 |
Market Cap | Rs m | 8,079 | 15,101 |
Dividends per share (Unadj.) | Rs | 0.0 | 0.0 |
Current Ratio: The company's current ratio deteriorated and stood at 0.8x during FY18, from 1.0x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.
Interest Coverage Ratio: The company's interest coverage ratio improved and stood at 0.3x during FY18, from 0.3x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.
Return on Equity (ROE): The ROE for the company declined and down at -24.7% during FY18, from -15.9% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.
Return on Capital Employed (ROCE): The ROCE for the company improved and stood at 3.9% during FY18, from 3.1% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.
Return on Assets (ROA): The ROA of the company declined and down at 1.5% during FY18, from 2.5% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.
No. of Mths Year Ending | 12 Mar-17* | 12 Mar-18* | |
---|---|---|---|
Current ratio | x | 1.0 | 0.8 |
Debtors’ Days | Days | 98 | 84 |
Interest coverage | x | 0.3 | 0.3 |
Debt to equity ratio | x | 2.0 | 1.8 |
Return on assets | % | 2.5 | 1.5 |
Return on equity | % | -15.9 | -24.7 |
Return on capital employed | % | 3.1 | 3.9 |
To see how PANACEA BIOTECH has performed over the last 5 years, please visit here.
Over the last one year, PANACEA BIOTECH share price has moved up from Rs 160.7 to Rs 267.1, registering a gain of Rs 106.4 or around 66.2%.
Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,157.6 (down 1.1%). Over the last one year it has moved down from 15,312.4 to 13,157.6, a loss of 2,155 points (down 14.1%).
Overall, the S&P BSE SENSEX is up 12.1% over the year.
(To know more, check out historical annual results for PANACEA BIOTECH and quarterly results for PANACEA BIOTECH)
PANACEA BIOTECH currently trades at Rs 138.4 per share. You can check out the latest share price performance of PANACEA BIOTECH here...
The revenues of PANACEA BIOTECH stood at Rs 5,977 m in FY18, which was up 3.6% compared to Rs 5,767 m reported in FY17.
PANACEA BIOTECH's revenue has fallen from Rs 8,646 m in FY07 to Rs 5,977 m in FY18.
Over the past 12 years, the revenue of PANACEA BIOTECH has grown at a CAGR of -3.3%.
The net loss of PANACEA BIOTECH stood at Rs -762 m in FY18, which was up 34.9% compared to Rs -565 m reported in FY17.
This compares to a net loss of Rs -209 m in FY16 and a net profit of Rs 1,290 m in FY08.
Over the past 12 years, PANACEA BIOTECH net profit has grown at a CAGR of NaN%.
The cash flow statement is the financial statement that presents the cash inflows and outflows of a company during a given period of time.
This statement is one of the most useful tools for judging a company's liquidity position. The ratios and parameters in this statement helps test a company's financial health.
The cash flow statement of PANACEA BIOTECH reveals:
Here's the cash flow statement of PANACEA BIOTECH for the past 12 years.
(Rs m) | FY07 | FY08 | FY16 | FY17 | FY18 |
---|---|---|---|---|---|
From Operations | 1,570 | 668 | 907 | 1,307 | 1,180 |
From Investments | 1,724 | -3,839 | 164 | -258 | 553 |
From Financial Activity | -2,350 | 2,211 | -1,174 | -1,070 | -1,643 |
Net Cashflow | 976 | -959 | -102 | -21 | 90 |
Be it the company's profitability, operations effectiveness or utilization of funds, ratio analysis is an important tool which helps in making investment decisions.
The ratio/financial analysis of PANACEA BIOTECH reveals:
Here's the ratio/financial analysis of PANACEA BIOTECH for the past 12 years.
FY07 | FY08 | FY16 | FY17 | FY18 | |
---|---|---|---|---|---|
Operating Profit Margin (%) | 26.9 | 24.1 | 24.7 | 10.3 | 14.3 |
Net Profit Margin (%) | 17.7 | 15.4 | -3.2 | -10.7 | -12.9 |
Debt to Equity Ratio (x) | 0.4 | 0.6 | 1.9 | 2.0 | 1.8 |
Read: Latest Annual Report Analysis of PANACEA BIOTECH
Equitymaster requests your view! Post a comment on "PANACEA BIOTECH 2017-18 Annual Report Analysis". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!